​

Design Therapeutics (DSGN) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

DSGN Stock Forecast

Design Therapeutics (DSGN) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $20.50, with a high of $21.00 and a low of $20.00. This represents a 92.31% increase from the last price of $10.66.

- $5 $10 $15 $20 $25 High: $21 Avg: $20.5 Low: $20 Last Closed Price: $10.66

DSGN Stock Rating

Design Therapeutics stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (57.14%), 3 Hold (42.86%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 3 4 Strong Sell Sell Hold Buy Strong Buy

DSGN Price Target Upside V Benchmarks

TypeNameUpside
StockDesign Therapeutics92.31%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-25
Avg Price Target-$20.50$17.60
Last Closing Price$10.66$10.66$10.66
Upside/Downside-92.31%65.10%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2625---7
May, 2624---6
Apr, 2624---6
Mar, 2623---5
Feb, 2623---5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 04, 2026Oppenheimer$21.00$13.3057.89%97.00%
Apr 29, 2026Piper Sandler$20.00$15.2531.15%87.62%
Jan 07, 2026Oppenheimer$18.00$8.82104.08%68.86%
Dec 03, 2025Adam VogelCraig-Hallum$15.00$8.9467.79%40.71%
Dec 03, 2025Joseph SchwartzLeerink Partners$14.00$8.9456.60%31.33%
May 07, 2024Yasmeen RahimiPiper Sandler$12.00$3.65228.77%12.57%
Aug 15, 2023Leonid TimashevRBC Capital$7.00$2.17222.58%-34.33%
Dec 07, 2022Yasmeen RahimiPiper Sandler$42.00$12.69230.97%294.00%
May 02, 2022RBC Capital$30.00$11.94151.26%181.43%
Jan 19, 2022Madhu KumarGoldman Sachs$10.00$13.98-28.47%-6.19%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 12, 2026Cantor FitzgeraldOverweightinitialise
May 04, 2026OppenheimerOutperformOutperformhold
Apr 29, 2026Piper SandlerOverweightOverweighthold
Jan 07, 2026OppenheimerOutperforminitialise
Dec 03, 2025Craig-HallumBuyinitialise
Nov 20, 2025RBC CapitalSector PerformOutperformupgrade
Aug 15, 2023RBC CapitalOutperformSector Performdowngrade
Dec 07, 2022Piper SandlerOverweightOverweighthold
May 02, 2022RBC CapitalOutperforminitialise
Jan 19, 2022Goldman SachsCautiousinitialise

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.19$-0.88$-1.22---
Avg Forecast$-1.30$-0.90$-1.21$-1.14$-1.19$-1.54
High Forecast$-1.27$-0.88$-1.08$-1.05$-1.19$-1.54
Low Forecast$-1.36$-0.92$-1.34$-1.24$-1.19$-1.54
Surprise %-8.46%-2.22%0.83%---

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$48.53M$117.33M$204.78M$10.00M
High Forecast--$50.12M$117.33M$204.78M$10.00M
Low Forecast--$46.94M$117.33M$204.78M$10.00M
Surprise %------

Net Income Forecast

$-90M $-81M $-72M $-63M $-54M $-45M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-66.86M$-49.59M$-69.79M---
Avg Forecast$-72.36M$-50.39M$-67.40M$-64.01M$-66.34M$-85.94M
High Forecast$-70.83M$-49.28M$-60.38M$-58.67M$-66.34M$-85.94M
Low Forecast$-76.40M$-51.49M$-74.89M$-69.34M$-66.34M$-85.94M
Surprise %-7.60%-1.58%3.55%---

DSGN Forecast FAQ

Is Design Therapeutics stock a buy?

Design Therapeutics stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Design Therapeutics is a favorable investment for most analysts.

What is Design Therapeutics's price target?

Design Therapeutics's price target, set by 7 Wall Street analysts, averages $20.5 over the next 12 months. The price target range spans from $20 at the low end to $21 at the high end, suggesting a potential 92.31% change from the previous closing price of $10.66.

How does Design Therapeutics stock forecast compare to its benchmarks?

Design Therapeutics's stock forecast shows a 92.31% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Design Therapeutics over the past three months?

  • June 2026: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Design Therapeutics’s EPS forecast?

Design Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.14, marking a -6.56% decrease from the reported $-1.22 in 2025. Estimates for the following years are $-1.19 in 2027, and $-1.54 in 2028.

What is Design Therapeutics’s revenue forecast?

Design Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $117.33M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $204.78M, and $10M for 2028.

What is Design Therapeutics’s net income forecast?

Design Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-64.009M, representing a -8.29% decrease from the reported $-69.792M in 2025. Projections indicate $-66.342M in 2027, and $-85.936M in 2028.